SCHEMBL2273993

SCHEMBL2273993

COC(=O)c1ccc(SCc2ccccc2)cc1NC(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.55
MAPK1 P28482 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MCL1 Q07820 1/20 0.53
BCL2A1 Q16548 1/20 0.53
HDAC3 O15379 3/20 0.52
NCOR1 O75376 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC2 Q92769 3/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
APOBEC3A P31941 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
ALDH1A1 P00352 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 3/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 2/20 0.48
HDAC4 P56524 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274042 0.88 KDM4E (0.57) KDM4EMAPK1HSD17B10HDAC3NCOR1
SCHEMBL2271190 0.88 MCL1 (0.64) KDM4EMCL1BCL2A1HDAC3NCOR1
SCHEMBL14428448 0.84 L3MBTL1 (0.50) KDM4EMCL1BCL2A1MEN1KMT2A
SCHEMBL2269880 0.83 KDM4E (0.60) KDM4EMAPK1HSD17B10MEN1KMT2A
SCHEMBL18152278 0.80 MCL1 (0.78) KDM4EMAPK1HSD17B10MCL1BCL2A1
SCHEMBL3165801 0.79 L3MBTL1 (0.52) MCL1BCL2A1MEN1KMT2AALDH1A1
SCHEMBL4216703 0.78 MAPT (0.50) KDM4EMCL1BCL2A1ALDH1A1MAPT
SCHEMBL2277733 0.77 KDM4E (0.64) KDM4EMAPK1HSD17B10HDAC1MEN1
SCHEMBL2275077 0.77 KDM4E (0.66) KDM4EMAPK1HSD17B10MEN1KMT2A
SCHEMBL2276099 0.77 KDM4E (0.66) KDM4EMAPK1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 KDM4E 1257/4885MAPK1 168/4885HSD17B10 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.